International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	COBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS
DOI	https://doi.org/10.31435/ijitss.1(49).2026.4695
RECEIVED	11 November 2025
ACCEPTED	03 January 2026
PUBLISHED	17 January 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

COBENFY (XANOMELINE-TROSPIUM CHLORIDE) AS A BREAKTHROUGH IN SCHIZOPHRENIA TREATMENT: POTENTIAL IMPACT ON PATIENT QUALITY OF LIFE AND HEALTHCARE ECONOMICS

Monika Wołosik *(Corresponding Author, Email: monikawolosikkk@wp.pl)*
Military Institute of Medicine in Warsaw, Mazovia, Poland
ORCID ID: 0009-0001-0129-4771

Natalia Bednarczyk
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
ORCID ID: 0009-0003-2070-8559

Rafał Bednarczyk
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
ORCID ID: 0009-0002-0139-8586

Radosław Krzysztof Binkowski
4th Military Clinical Hospital with Polyclinic in Wroclaw, Wroclaw, Poland
ORCID ID: 0009-0009-5925-1158

Agnieszka Kurek
Military Institute of Medicine in Warsaw, Mazovia, Poland
ORCID ID: 0009-0000-7906-213X

Natalia Krajewska
Military Institute of Aviation Medicine in Warsaw, Mazovia, Poland
ORCID ID: 0009-0001-0508-5790

Aleksandra Lejman
10th Military Clinical Hospital with Independent Public Healthcare Centre Polyclinic in Bydgoszcz, Bydgoszcz, Poland
ORCID ID: 0009-0005-8637-2204

Aleksandra Mazurkiewicz
1st Military Clinical Hospital with Outpatient Clinic in Lublin, Lublin, Poland
ORCID ID: 0009-0008-9074-3583

Hubert Sidor
Military Institute of Medicine in Warsaw, Mazovia, Poland
ORCID ID: 0009-0005-5432-9279

Szymon Zysiak
Military Institute of Aviation Medicine in Warsaw, Mazovia, Poland
ORCID ID: 0009-0002-8803-5736

ABSTRACT

In September 2024 FDA approved Cobenfy - the first antipsychotic with a novel mechanism of action in over 30 years. Unlike conventional antipsychotics that block D2 dopamine receptors, Cobenfy acts through muscarinic M1 and M4 receptor agonism. This matters because the side effects of traditional antipsychotics - weight gain, metabolic disturbances, movement disorders - are the main reason why about half of patients stop taking their medications. And when they stop, relapses follow. The EMERGENT trials demonstrated that Cobenfy achieves comparable efficacy (effect size 0.61) while avoiding the metabolic and extrapyramidal problems that plague existing treatments. For patients with schizophrenia, who already face a 15-20 year reduction in life expectancy largely due to cardiovascular disease, a medication that doesn't worsen their metabolic profile could be genuinely life-changing. But beyond individual health the implications extend to families exhausted by relapse cycles, to healthcare systems burdened by preventable hospitalizations, and to communities that have struggled to integrate people whose treatment makes normal functioning nearly impossible. Of course long-term data are still needed - approval came after relatively short trials. But the potential here is significant: better tolerability could mean better adherence, fewer relapses, less hospitalization, and ultimately patients who can actually participate in their own lives.

KEYWORDS

Cobenfy, Xanomeline-Trospium, Schizophrenia, Muscarinic Agonist, Treatment Adherence, Quality of Life, Antipsychotic Side Effects, Social Functioning, Healthcare Economics

CITATION

Monika Wołosik, Natalia Bednarczyk, Rafał Bednarczyk, Radosław Krzysztof Binkowski, Agnieszka Kurek, Natalia Krajewska, Aleksandra Lejman, Aleksandra Mazurkiewicz, Hubert Sidor, Szymon Zysiak (2026) Cobenfy (Xanomeline-Trospium Chloride) as a Breakthrough in Schizophrenia Treatment: Potential Impact on Patient Quality of Life and Healthcare Economics. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.4695

1. Introduction

Schizophrenia affects around 24 million people worldwide. According to GBD data, approximately 1.22 million new cases were diagnosed in 2021 alone (World Health Organization, 2022). The disorder typically strikes in late adolescence or early adulthood - precisely when people are building careers, forming relationships, establishing independence. This timing is cruel. It means schizophrenia doesn't just affect individuals; it derails entire life trajectories.

These aren't just statistics - these are people whose lives are fundamentally altered by a condition that shortens life expectancy by 15-20 years, primarily due to cardiovascular complications (Hjorthøj et al., 2017). But mortality is only part of the picture. Employment rates among people with schizophrenia hover between 10-30% in most developed countries, compared to 70-80% in the general population (Marwaha & Johnson, 2004). Think about what that means: the vast majority of people with this illness are excluded from the workforce, from the income and structure and social connections that employment provides. Marriage rates are dramatically lower. Social networks shrink. Many patients describe profound loneliness - not because they don't want connection but because the illness and its treatment create barriers that feel insurmountable. The social exclusion often begins before treatment even starts - the prodromal period of withdrawal and odd behavior leads to lost friendships and damaged family relationships. But treatment, paradoxically, can make social reintegration harder rather than easier when it comes with visible side effects that invite further stigma.

The treatment landscape has been essentially unchanged since the 1950s. We've had first-generation antipsychotics, then second-generation, but they all work the same basic way: blocking dopamine D2 receptors. Yes, newer drugs reduced some of the movement disorders that made older medications so difficult to tolerate - the dystonia, the shuffling gait, the tremor that marked patients as visibly different and invited stigma. But second-generation antipsychotics introduced their own problems: significant weight gain, metabolic syndrome, diabetes risk. A patient might start olanzapine at a healthy weight and gain 15 kg in the first year. That's not a

minor inconvenience. For patients already vulnerable to cardiovascular disease these side effects aren't just inconvenient. They're potentially fatal.

Here's what's frustrating about the current situation: we know that approximately 50% of patients discontinue their medications (Velligan et al., 2009). We know the main reason is side effects - not because the medications don't work, but because patients can't tolerate what they do to their bodies. We know that stopping medication is the strongest predictor of relapse - about 80% of patients relapse within the first year after discontinuation (Tiihonen et al., 2018). And yet for decades we've kept prescribing drugs that patients can't or won't tolerate, essentially accepting that half our patients will fail treatment not because the treatment doesn't work, but because its costs are too high.

This creates a vicious cycle that extends far beyond the individual patient. Patient takes medication, gains 20 kg, feels terrible about themselves, faces additional stigma related to their appearance, stops taking medication, relapses, loses their job, ends up hospitalized - often involuntarily - cycle repeats. Each iteration makes things worse. Jobs are lost that took months to find. Relationships break down under the strain. Housing may be lost. The social capital that patients need to maintain community integration erodes with each cycle. Figure 1 illustrates this relapse cycle and demonstrates how Cobenfy's improved tolerability profile might help break it.

The burden extends to families. Caregivers of people with schizophrenia experience elevated rates of depression, anxiety, and physical health problems (Awad & Voruganti, 2008). Many reduce work hours or leave employment entirely to provide care. Parents who expected to be empty-nesters find themselves providing indefinite support for adult children. Siblings take on responsibilities they never anticipated. The economic impact of informal caregiving is enormous but largely invisible in healthcare cost analyses.

So when the FDA approved Cobenfy in September 2024, it caught our attention. Not because it's necessarily more effective at controlling symptoms - it's roughly comparable to existing drugs. But because it works through an entirely different mechanism: muscarinic receptor agonism instead of dopamine blockade. And that difference in mechanism translates to a very different side effect profile - one that might finally allow patients to stay on treatment without sacrificing their physical health, their appearance, or their ability to engage with the world.



Fig. 1. *The relapse cycle in schizophrenia. Side effects from conventional antipsychotics lead to medication discontinuation (~50% of patients), which results in relapse (~80% within one year) and hospitalization. Each cycle compounds social consequences including job loss, relationship breakdown, and housing instability. Cobenfy's improved tolerability profile may help break this cycle. EPS = extrapyramidal symptoms. Based on data from Velligan et al. (2009) and Tiihonen et al. (2018).*

2. Methods

This paper represents a narrative review of published literature on Cobenfy (xanomeline-trospium chloride), with particular attention to dimensions relevant to patient quality of life, social functioning, and healthcare economics. We searched PubMed, ClinicalTrials.gov, and FDA regulatory documents using terms including "Cobenfy," "KarXT," "xanomeline-trospium," "muscarinic agonist schizophrenia," and combinations with "quality of life," "adherence," and "economic burden." The primary sources were the EMERGENT trial publications (Brannan et al., 2021; Kaul et al., 2024a; Kaul et al., 2024b), pooled analyses (Kaul et al., 2024c; Kaul et al., 2025), and the Leucht meta-analysis comparing antipsychotic efficacy (Leucht et al., 2013). For economic context we reviewed systematic reviews on schizophrenia costs (Chong et al., 2016). We also examined post-hoc analyses on cognitive effects (Sauder et al., 2022), literature on negative symptoms (Correll & Schooler, 2020; Fervaha et al., 2014), and research on employment outcomes (Marwaha & Johnson, 2004) and caregiver burden (Awad & Voruganti, 2008).

We should acknowledge upfront: this is not a systematic review. We did not use formal quality assessment tools or attempt to be exhaustive. We are a group of physicians interested in psychiatry trying to make sense of whether this new drug represents a genuine advance or just pharmaceutical marketing. Our goal is to examine what we actually know, what we don't know yet and what this might mean for patients, families, and healthcare systems. We've tried to present data fairly while acknowledging the limitations of available evidence.

3. Results

3.1 How Cobenfy works

Cobenfy combines two compounds: xanomeline and trospium chloride. The interesting pharmacology is in the xanomeline - it's an agonist at M1 and M4 muscarinic acetylcholine receptors. This represents the first fundamentally new mechanism for treating schizophrenia since chlorpromazine was introduced in the 1950s. Instead of blocking dopamine directly, xanomeline modulates dopaminergic activity in the mesolimbic system through cholinergic pathways. M1 receptors are distributed throughout the cortex and hippocampus, where they play crucial roles in cognitive function and memory. M4 receptors are concentrated in the striatum and modulate dopamine release in regions associated with psychosis.

The idea that cholinergic systems matter in schizophrenia isn't new - researchers have known for decades that muscarinic receptors are altered in the brains of people with the disorder. But translating this knowledge into treatment proved difficult. Xanomeline alone was tested in the 1990s and showed antipsychotic effects, but it failed in development because peripheral muscarinic activation caused intolerable gastrointestinal side effects - nausea, vomiting, diarrhea that made the drug unusable. The clever innovation in Cobenfy is adding trospium chloride, a muscarinic antagonist that blocks peripheral muscarinic receptors but doesn't cross the blood-brain barrier. So you get central nervous system effects from xanomeline without the peripheral side effects that derailed earlier development. It took decades to figure this out, but it's an elegant solution.

What's significant about avoiding D2 blockade: no extrapyramidal symptoms (the movement disorders that mark patients as visibly different), no tardive dyskinesia risk (often irreversible), no prolactin elevation (which causes sexual dysfunction and other problems). And crucially - no affinity for the receptors that cause weight gain and metabolic problems. The H1 histamine receptor blockade that causes weight gain with olanzapine and clozapine? Cobenfy doesn't touch it. The 5-HT2C receptor antagonism that contributes to metabolic dysregulation? Not part of Cobenfy's profile. This isn't just a technical pharmacological detail - it's the reason patients might actually be able to take this medication long-term without destroying their physical health in the process. Table 1 summarizes the key differences between Cobenfy and conventional antipsychotics.

Table 1. Comparison of Cobenfy with conventional antipsychotics

Characteristic	Cobenfy	First-generation (e.g., haloperidol)	Second-generation (e.g., olanzapine)
Mechanism of action	M1/M4 muscarinic agonism	D2 dopamine antagonism	D2 + 5-HT2A antagonism
Efficacy (effect size)	0.61	0.45–0.66	0.33–0.88
Weight gain	None / weight loss	Minimal	Significant (5–10 kg/year)
EPS risk	None	High	Low to moderate
Tardive dyskinesia	Not observed	3–5% per year	0.5–1% per year
Metabolic effects	None	Minimal	Dyslipidemia, diabetes risk
Prolactin elevation	None	High	Variable
Sedation	Minimal	Moderate to high	Moderate to high
Main side effects	Constipation, nausea, dry mouth	EPS, sedation, akathisia	Weight gain, sedation, metabolic

Note. EPS = extrapyramidal symptoms; 5-HT2A = serotonin 2A receptor. Effect sizes based on Leucht et al. (2013) meta-analysis and EMERGENT trial data (Kaul et al., 2024a, 2024b). Weight and metabolic data from Pillinger et al. (2020) and Kaul et al. (2025).

3.2 Clinical efficacy data

The EMERGENT-2 and EMERGENT-3 trials were both 5-week, randomized, double-blind, placebo-controlled studies in adults with acute schizophrenia. EMERGENT-2 enrolled 252 patients across 22 US sites; EMERGENT-3 enrolled 256 patients across 30 sites in the US and Ukraine. An earlier phase 2 study (Brannan et al., 2021) with 182 patients had already shown proof of concept, with a 17.4-point improvement in PANSS total score compared to 5.9 points for placebo - a substantial difference that justified proceeding to phase 3.

Results from the pivotal trials: EMERGENT-2 showed a 9.6-point improvement in PANSS total score versus placebo (95% CI 5.2-13.9, $p<0.0001$). EMERGENT-3 showed an 8.4-point improvement (95% CI 4.4-12.4, $p<0.001$). The standardized effect size was 0.61 - which according to Leucht's comprehensive meta-analysis of 15 antipsychotics puts Cobenfy right in line with existing effective treatments (Kaul et al., 2024a; Kaul et al., 2024b). For context, haloperidol shows effect sizes of 0.45-0.66, olanzapine 0.59-0.88, risperidone 0.56. Cobenfy isn't more effective than these drugs - but it's not less effective either.

Both trials showed improvement in positive symptoms (hallucinations, delusions) AND negative symptoms (reduced motivation, emotional blunting, social withdrawal). The negative symptom finding is potentially important. Negative symptoms are notoriously difficult to treat with conventional antipsychotics - most drugs do essentially nothing for them. Yet negative symptoms are often more disabling than positive symptoms in terms of patients' ability to work, maintain relationships, and live independently. A patient whose hallucinations are controlled but who has no motivation to get out of bed isn't functioning well. The improvement in negative symptoms with Cobenfy may relate to M1 receptor effects on motivation and cognition, though this needs more study.

Pooled analysis confirmed consistent effects across subgroups regardless of age, sex, race, baseline severity, or prior antipsychotic use (Kaul et al., 2024c). This consistency matters for clinical practice - it suggests that Cobenfy's benefits aren't limited to particular patient populations but may be broadly applicable. Response rates (defined as ≥30% improvement in PANSS) and remission rates were significantly higher with Cobenfy than placebo, which is what patients and families actually care about: not just statistical improvement but meaningful clinical change. The question that trials can't fully answer is whether these benefits persist over months and years of treatment - something we'll only learn from real-world experience and longer-term studies.

3.3 Side effect profile - this is where it gets interesting

If efficacy data tell us whether a drug can work, tolerability data tell us whether patients can actually take it. And this is where Cobenfy may represent its most significant advance.

The most common adverse effects with Cobenfy were cholinergic in nature: constipation (21% vs 6% placebo), nausea (17% vs 4%), dry mouth (9% vs 2%), dyspepsia (9% vs 3%), vomiting (7% vs 3%). Generally mild to moderate and transient - the kind of side effects that patients can work around, not the kind that upend their lives.

Here's what wasn't seen: no evidence of weight gain compared to placebo. No metabolic abnormalities - no changes in lipids, glucose, or other metabolic parameters. No extrapyramidal symptoms. No akathisia (that unbearable inner restlessness that drives some patients to suicide). No tardive dyskinesia. In fact in the

52-week extension data, patients actually lost weight - average 2.6 kg, with about 66% of patients showing weight loss rather than gain (Kaul et al., 2025). This is remarkable. It's the opposite of what we see with most second-generation antipsychotics.

Think about what this means for patients. Someone starting olanzapine might gain 10-15 kg in the first year. That weight gain isn't just a number on a scale. It affects how patients see themselves in the mirror. It affects how others see them - and people are not kind to those who gain significant weight. It increases cardiovascular risk in a population already dying 15-20 years early from cardiovascular disease. It often leads patients to stop a medication that is otherwise controlling their symptoms. Someone on Cobenfy might instead maintain their weight or even lose a few kilograms while achieving symptom control. That's not a minor difference.

Discontinuation rates tell a similar story. In the EMERGENT trials, discontinuation due to adverse effects was similar between Cobenfy (6%) and placebo (4%). Compare this to olanzapine trials where 15-20% discontinue for adverse effects. The FDA label does include warnings about dose-dependent increases in heart rate (average 10-12 bpm) and urinary retention (particularly relevant for older men with prostatic hyperplasia). Cobenfy is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. These are real considerations that will limit use in some patients. But for most patients, these risks seem far more manageable than the metabolic burden of conventional antipsychotics.

Perhaps equally important is the subjective experience. The emotional blunting, cognitive dulling, and zombie-like feeling that many patients describe on conventional antipsychotics appears largely absent with Cobenfy. Patients in the trials reported feeling more like themselves - more able to think clearly, feel emotions, engage with their lives. We need more formal quality-of-life data to confirm this, but if true, it may be as important as the objective side effect measurements in determining whether patients actually stay on treatment. There's a reason patients sometimes say they'd rather deal with symptoms than feel like a zombie - and a medication that controls symptoms without that trade-off could be genuinely transformative for adherence.

3.4 Economic considerations

Schizophrenia generates enormous economic costs - and they fall in ways that aren't always visible in healthcare budgets. A comprehensive systematic review by Chong et al. (2016) found total costs ranging from under $100 million annually in smaller countries to over $100 billion in the United States. The most rigorous U.S. estimate placed total costs at $155.7 billion in 2013 dollars - a figure that has almost certainly increased. To put this in perspective, that exceeds the GDP of many countries.

What makes schizophrenia economically distinctive is the distribution of costs. Direct healthcare costs - hospitalizations, medications, outpatient visits - account for only 15-50% of total burden depending on the analysis. The majority of costs, typically 50-85%, are indirect: lost productivity from patients unable to work, disability payments, lost productivity from family caregivers who reduce work hours or leave employment, premature mortality, and involvement with criminal justice systems. These indirect costs are largely invisible in healthcare budget analyses but represent enormous societal burden.

Much of this cost stems from the relapse cycle. Each psychotic relapse requiring hospitalization costs $15,000-30,000 in direct expenses. But the true cost extends far beyond the hospital bill. Patients often lose jobs during hospitalization - jobs that took months of supported employment to obtain. Housing may be lost, leading to homelessness or returns to family homes that strain relationships. Each relapse chips away at the social capital patients need to maintain community integration.

The caregiver burden deserves specific attention. Family members provide the majority of care for people with schizophrenia, yet this labor is largely invisible economically. Studies suggest caregivers lose an average of 4-8 working hours per week to caregiving responsibilities, with many leaving employment entirely (Awad & Voruganti, 2008). The stress of caregiving leads to elevated rates of depression and physical health problems among family members. Parents age while still providing care they expected to stop providing decades earlier. Siblings sacrifice their own opportunities. Spouses and partners burn out. When we calculate the cost of schizophrenia, we need to include these ripple effects on families and communities - costs that don't show up in healthcare budgets but are devastatingly real.

Cobenfy will certainly be more expensive than generic antipsychotics in terms of acquisition cost. Bristol Myers Squibb acquired Karuna Therapeutics for $14 billion - they'll need to price the medication to recoup that investment. Brand-name antipsychotics typically cost $500-1,500 per month compared to $10-50 for generic alternatives. This will create access barriers, particularly for patients without adequate insurance or in healthcare systems with restricted formularies.

But here's the economic argument for Cobenfy: if better tolerability translates to better adherence, and better adherence translates to fewer relapses and hospitalizations, the math might actually work out. A single prevented hospitalization could pay for 1-2 years of medication. Maintaining employment shifts a patient from consuming disability resources to contributing tax revenue. Reduced caregiver burden allows family members to maintain their own productivity. This is speculation at this point - we need real-world data on adherence rates and healthcare utilization. But the logic is sound, and policymakers should consider total costs rather than just medication acquisition costs when making formulary decisions.

3.5 Quality of life - the part that doesn't show up in PANSS scores

Research consistently shows that side effects predict quality of life sometimes more strongly than symptoms themselves (Awad & Voruganti, 2008). This seems paradoxical until you think about what it means to live with schizophrenia treatment, not just schizophrenia.

A patient whose psychosis is controlled but who has gained 30 kg and developed diabetes is not living well. The weight gain affects self-esteem and body image. Patients describe avoiding social situations because of embarrassment about their appearance. Dating and romantic relationships become more difficult. Employment in customer-facing roles may be affected - there's substantial evidence of weight discrimination in hiring. The stigma of mental illness gets compounded by weight stigma, creating intersecting barriers to social inclusion.

Movement disorders create their own social burdens. The tremor, rigidity, and restlessness of extrapyramidal symptoms are visible markers that invite stigma and discrimination. Patients describe being stared at on public transportation, assumed to be dangerous or "crazy," denied employment because of visible symptoms that have nothing to do with their ability to work. Tardive dyskinesia - with its involuntary facial movements - is particularly stigmatizing and often irreversible. In a cruel irony, the medications meant to help patients rejoin society create new barriers to social inclusion.

Sedation may be the most underappreciated problem. Patients on sedating antipsychotics describe sleeping 12-14 hours daily, lacking energy for activities, being unable to work or attend school. Employment rates in schizophrenia are already dismal (10-30%), and sedating medications likely contribute. A patient who can't stay awake through a workday can't hold a job, regardless of whether their psychotic symptoms are controlled. Social relationships require energy and initiative that sedating medications preclude. Some patients describe the sedation as worse than the illness itself - at least with psychosis they felt alive, even if their perceptions were distorted. The sedation robs them of the capacity to engage with life at all.

By eliminating or dramatically reducing these side effects, Cobenfy removes barriers that have nothing to do with psychosis but everything to do with whether patients can actually live their lives. A patient on Cobenfy might maintain normal weight, have no visible movement disorders, experience no sedation, and preserve their emotional range and cognitive function. That patient has a fighting chance at employment, relationships, and community integration in ways that patients on conventional antipsychotics often don't.

Early data also suggest potential benefits for cognitive function through M1 receptor agonism (Sauder et al., 2022). Cognitive impairment in schizophrenia - affecting attention, memory, processing speed, and executive function - is a major driver of functional disability and is largely unaddressed by conventional antipsychotics. If Cobenfy can improve or at least not worsen cognition, combined with its benefits on negative symptoms, it might help patients return to work and maintain relationships - outcomes that matter far more than PANSS scores.

We should also mention the concept of self-stigma - when patients internalize society's negative views of mental illness and come to see themselves as damaged or incapable. Self-stigma predicts poor functional outcomes even controlling for symptoms. A medication that allows patients to maintain normal appearance, think clearly, and function without visible impairment may help patients resist self-stigma and pursue opportunities they might otherwise avoid. This isn't about hiding illness; it's about allowing patients the same dignity of privacy that people with other chronic conditions enjoy.

4. Discussion

We want to be clear about what Cobenfy is and isn't. It's not a cure - no such cure exists. It's not dramatically more effective than existing medications at controlling positive symptoms. It won't eliminate the need for psychosocial interventions, supported employment, family involvement, and the other non-pharmacological elements essential to good treatment. And it won't be right for all patients - those with urinary retention, gastric retention, or narrow-angle glaucoma can't take it, and we still need more long-term data.

What it offers is a different side effect profile - and in psychiatry, where treatment success depends entirely on patients actually taking their medications, that matters enormously. The gap between efficacy in controlled trials and effectiveness in real-world practice is nowhere greater than in schizophrenia, where approximately half of patients discontinue treatment within a year. If even a fraction of those discontinuations are driven by side effects that Cobenfy avoids, the real-world impact could be substantial.

The approval came after two 5-week trials with 470 total participants in the pivotal studies. That's not a lot of data for a medication patients might take for decades. We know Cobenfy works at 5 weeks - we don't know whether efficacy is maintained over months and years. We know it appears metabolically neutral in short-term studies - we don't know about effects over years of exposure. The open-label extension studies are encouraging but inherently limited by selection bias - they include only patients who tolerated and responded to treatment initially. We need post-marketing surveillance to catch rare adverse effects, long-term studies to assess durability of response, and real-world effectiveness research to understand how Cobenfy performs outside the controlled conditions of clinical trials.

Who might benefit most? Based on its profile, we'd suggest patients who have struggled with weight gain or metabolic effects on conventional antipsychotics - the substantial proportion who gain significant weight on olanzapine, clozapine, or quetiapine. Patients who have discontinued previous treatment due to side effects. Perhaps patients with prominent negative symptoms or cognitive impairment who might benefit from M1 agonism. And possibly patients experiencing first-episode psychosis, where avoiding metabolic complications from the start could have long-term benefits and where establishing good adherence patterns is crucial.

Cost will be a barrier. Brand-name pricing will limit access, particularly in lower-income countries, for patients without adequate insurance, or in healthcare systems with restricted formularies. The irony of developing a medication that could improve functioning and reduce long-term costs but pricing it beyond reach of many patients is not lost on us.

And we shouldn't forget: pharmacotherapy is only part of schizophrenia treatment. Psychosocial interventions - cognitive behavioral therapy, social skills training, supported employment, family psychoeducation - have strong evidence and improve outcomes beyond what medications alone achieve. A better-tolerated medication might actually facilitate engagement with these other interventions by allowing patients to think more clearly and feel better about themselves. The best outcomes will likely come from combining Cobenfy's improved tolerability with comprehensive psychosocial support.

5. Conclusions

Cobenfy represents something genuinely new - the first novel mechanism for schizophrenia treatment in 30 years. Its value lies not in superior efficacy but in a side effect profile that might actually allow patients to stay on treatment without sacrificing their physical health, their appearance, their cognitive function, or their sense of self.

For a disease where non-adherence drives relapses, hospitalizations, and progressive deterioration this matters enormously. For patients who have had to choose between controlling their psychosis and controlling their weight, this offers an alternative. For families exhausted by cycles of relapse and recovery, this offers hope for stability. For healthcare systems spending billions on preventable hospitalizations, this might eventually reduce costs. For a society that has marginalized people with schizophrenia - sometimes because of the very treatments meant to help them - this offers a chance to do better.

We need more data. We need to see how this performs over years, not weeks. We need to understand how it works in real-world settings with real patients who have comorbidities and complicated lives and don't always take their medications exactly as prescribed. We need health economic studies to quantify benefits and inform pricing decisions. We need to know which patients benefit most and whether benefits extend to treatment-resistant cases. And we need to ensure that pricing doesn't put this medication out of reach for the patients who need it most.

But the fundamental promise - an effective antipsychotic that doesn't cause the side effects that drive patients away from treatment and away from full participation in society - is worth being cautiously optimistic about. For too long we've accepted that treating schizophrenia means choosing between symptom control and quality of life. Cobenfy suggests we might not have to make that choice. That's worth pursuing.

Author's contribution:

Research and concept design: Monika Wołosik, Hubert Sidor, Aleksandra Mazurkiewicz

Data collection and methodology: Rafał Bednarczyk, Aleksandra Lejman, Agnieszka Kurek, Radosław Krzysztof Binkowski

Formal analysis: Natalia Krajewska, Natalia Bednarczyk, Aleksandra Lejman, Hubert Sidor

Interpretation: Radosław Krzysztof Binkowski, Szymon Zysiak, Agnieszka Kurek

Writing: Monika Wołosik, Aleksandra Mazurkiewicz, Natalia Krajewska

Critical review of the article: Szymon Zysiak, Natalia Bednarczyk, Rafał Bednarczyk

Supervision, project administration: Monika Wołosik

All authors have read and agreed to the published version of the manuscript.

Funding Statement:The article did not receive any funding.

Institutional Review Board Statement: Not applicable; this review included only published data.

Data Availability Statement: All supporting data are available within the cited peer-reviewed literature.

Acknowledgments: The author acknowledges the contribution of investigators and data curators whose high-quality research underpins the advances reviewed herein.

Conflict of Interest Statement: No conflicts of interest to declare.

REFERENCES

1. Awad, A. G., & Voruganti, L. N. P. (2008). The burden of schizophrenia on caregivers: A review. *Pharmacoeconomics, 26*(2), 149–162. https://doi.org/10.2165/00019053-200826020-00005
2. Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021). Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. *New England Journal of Medicine, 384*(8), 717–726. https://doi.org/10.1056/NEJMoa2017015
3. Chong, H. Y., Teoh, S. L., Wu, D. B., Kotirum, S., Chiber, C. F., & Chaiyakunapruk, N. (2016). Global economic burden of schizophrenia: A systematic review. *Neuropsychiatric Disease and Treatment, 12*, 357–373. https://doi.org/10.2147/NDT.S96649
4. Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatric Disease and Treatment, 16*, 519–534. https://doi.org/10.2147/NDT.S225643
5. Fervaha, G., Foussias, G., Agid, O., & Remington, G. (2014). Impact of primary negative symptoms on functional outcomes in schizophrenia. *European Psychiatry, 29*(7), 449–455. https://doi.org/10.1016/j.eurpsy.2014.01.007
6. Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. *The Lancet Psychiatry, 4*(4), 295–301. https://doi.org/10.1016/S2215-0366(17)30078-0
7. Kaul, I., Sawchak, S., Correll, C. U., Kakar, R., Breier, A., Zhu, H., Miller, A. C., Paul, S. M., & Brannan, S. K. (2024a). Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2). *The Lancet, 403*(10422), 160–170. https://doi.org/10.1016/S0140-6736(23)02190-6
8. Kaul, I., Sawchak, S., Walling, D. P., Tamminga, C. A., Breier, A., Zhu, H., Miller, A. C., Paul, S. M., & Brannan, S. K. (2024b). Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial (EMERGENT-3). *JAMA Psychiatry, 81*(8), 749–756. https://doi.org/10.1001/jamapsychiatry.2024.0785
9. Kaul, I., Sawchak, S., Claxton, A., Sauder, C., Hassman, H. H., Kakar, R., Marcus, R., Paul, S. M., & Brannan, S. K. (2024c). Efficacy of xanomeline and trospium chloride in schizophrenia: Pooled results from three EMERGENT trials. *Schizophrenia, 10*, Article 102. https://doi.org/10.1038/s41537-024-00525-6
10. Kaul, I., Claxton, A., Sawchak, S., Sauder, C., Brannan, S. K., Raj, E., Zhu, H., & Marcus, R. (2025). Safety and tolerability of xanomeline and trospium chloride in schizophrenia: Pooled results from the EMERGENT trials. *Journal of Clinical Psychiatry, 86*(1), Article 24m15497. https://doi.org/10.4088/JCP.24m15497
11. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. *The Lancet, 382*(9896), 951–962. https://doi.org/10.1016/S0140-6736(13)60733-3

12. Marwaha, S., & Johnson, S. (2004). Schizophrenia and employment: A review. *Social Psychiatry and Psychiatric Epidemiology, 39*(5), 337–349. https://doi.org/10.1007/s00127-004-0762-4
13. Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. *The Lancet Psychiatry, 7*(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
14. Sauder, C., Allen, L. A., Baker, E., Miller, A. C., Paul, S. M., & Brannan, S. K. (2022). Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: Post hoc analyses of a phase 2 study. *Translational Psychiatry, 12*, Article 491. https://doi.org/10.1038/s41398-022-02254-9
15. Tiihonen, J., Tanskanen, A., & Taipale, H. (2018). 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. *American Journal of Psychiatry, 175*(8), 765–773. https://doi.org/10.1176/appi.ajp.2018.17091001
16. Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., & Docherty, J. P. (2009). The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. *Journal of Clinical Psychiatry, 70*(Suppl 4), 1–46. https://doi.org/10.4088/JCP.7090su1cj
17. World Health Organization. (2022). *Schizophrenia*. https://www.who.int/news-room/fact-sheets/detail/schizophrenia